Replies to post #105498 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

That is the million dollar question...

Now this stock's float is over 1.8 billion shares

Where did you get the 1.8B figure? Last published count was 1.3B. However, it's correct to consider the Dec 2016 run on pre-IND nonsense was performed with an O/S 65% of what it is today. By Jan 2017, the run was over, with the stock fading from 0.17 to 0.10.

There are two other factors to consider...

1. Longs still looking for shares in the Dec 2016 time period were probably diving into the euphoria. Presently tapped out. They aren't going to be buying more, while at the same time bidding it up, and then supporting the run with yet more buying. All of that now depends on Kenny or one of the 3rd parties staging yet another promo. The last promo gives a hint of what could happen.

2. At the end of 2016 potential dilution was coming from a Shelf filing back in 2014. Part of it was used for the various mergers back then. It's unknown unless one spends the time going through all the subsequent form 10s, as to how much of that Shelf filing was still to be dumped. The biggy question is: Was there more or less dilution occurring during in Dec 2016-Jan 2017, vs the potential dilution this time. Keeping in mind a 2nd Shelf filing occurred in Sep 2017.

The only thing in the near term for long's big pay day will be if thermo wants to buys pmcb out for .35cent which is a good half billion dollars based on current os.

That's not going to happen. Go to the TF website, and review their product lines. There is no fit. Neither would a TF or anyone else have to buy AN (not PMCB) to setup their own facilities. They aren't interested in buying a 3 room facility in Thailand. The CIABs no longer have patent protection. Then again, no one is interested in pursuing CIABs.

The other theme in various posts is that the Kenny Wonder Treatment will have pharma knocking on Kenny's doors. Calculate potential revenue as a 2nd line treatment, assuming it doesn't fail 5 yrs of CTs. Finally ask: Why would anyone pay $1B+ for a 2nd line treatment, where it will take 15+ yrs to recoup acquisition, and CT costs? Yet that is what the acquisition dreams are based on.

Reality is it all comes down to how effective the promos are, if and when the mythical IND is ever filed.